Interventions for mycosis fungoides: critical commentary on a Cochrane Systematic Review.

about

Response to 'Interventions for mycosis fungoides: critical commentary on a Cochrane Systematic Review'.Treatment of localized mycosis fungoides with digital UV photochemotherapy.

P2860

Q38212881-B1153FC6-F258-4248-905F-A0A8A16E5DD9 Q40306310-0B8BD2D6-EF33-4A2F-BCBF-FF3228D452F8

P2860

Interventions for mycosis fungoides: critical commentary on a Cochrane Systematic Review.

Item

http://www.wikidata.org/entity/Q38212880

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Interventions for mycosis fungoides: critical commentary on a Cochrane Systematic Review.

@en

type

Item

label

Interventions for mycosis fungoides: critical commentary on a Cochrane Systematic Review.

@en

prefLabel

Interventions for mycosis fungoides: critical commentary on a Cochrane Systematic Review.

@en

P1476

Interventions for mycosis fungoides: critical commentary on a Cochrane Systematic Review.

@en

P2093

M E Bigby

http://www.w3.org/2001/XMLSchema#string

P A Wu

http://www.w3.org/2001/XMLSchema#string

V Huang

http://www.w3.org/2001/XMLSchema#string

P2860

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Significant impact of cutaneous T-cell lymphoma on patients' quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey.

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with O⁶-methylguanine-DNA methyltransferase and mismatch repair proteins.

Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.

Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial.

Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients.

Narrowband ultraviolet B phototherapy of early stage mycosis fungoides in korean patients.

P304

1015-1020

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJD.12954

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

170

http://www.w3.org/2001/XMLSchema#string

P577

2014-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24841586

http://www.w3.org/2001/XMLSchema#string

Interventions for mycosis fungoides: critical commentary on a Cochrane Systematic Review.

about

P2860

P2860

Interventions for mycosis fungoides: critical commentary on a Cochrane Systematic Review.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698